Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trial Not Allowed
ArchivedFood and Drug Administration
Description
CBER, FDA seeks to support the development of innovative pathogen reduction technologies for whole blood and blood components to prevent transfusion-transmitted infectious diseases.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
Gordana Zuber <br/>Grant Management Specialist <br/>Phone 301-348-1747
gordana.zuber@fda.hhs.gov
Key dates & funding
- PostedFeb 18, 2020
- ClosesMay 26, 2020
- Award floor$1,600,000
- Award ceiling$8,000,000
- Expected awards5
- CFDA93.103
Categories
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro